Gut Microbiome in Progressive Multiple Sclerosis
Laura M. Cox,Amir Hadi Maghzi,Shirong Liu,Stephanie K. Tankou,Fyonn H. Dhang,Valerie Willocq,Anya Song,Caroline Wasén,Shahamat Tauhid,Renxin Chu,Mark C. Anderson,Philip L. De Jager,Mariann Polgar‐Turcsanyi,Brian C. Healy,Bonnie I. Glanz,Rohit Bakshi,Tanuja Chitnis,Howard L. Weiner
DOI: https://doi.org/10.1002/ana.26084
IF: 11.2
2021-04-30
Annals of Neurology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>Investigate the gut microbiome in progressive multiple sclerosis (MS) and how it relates to clinical disease.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We sequenced the microbiota from healthy controls, relapsing remitting MS (RRMS), and progressive MS patients and correlated the levels of bacteria with clinical features of disease, including EDSS, quality of life, and brain MRI lesions/atrophy. We colonized mice with MS‐derived <i>Akkermansia</i> and induced experimental autoimmune encephalomyelitis. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Microbiota β‐diversity differed between MS patients vs. controls but did not differ between RRMS vs. progressive MS or differ based on disease modifying therapies. Disease status had the greatest effect on the microbiome β‐diversity, followed by BMI, race, and sex. In both progressive and RRMS, we found increased <i>Clostridium bolteae, Ruthenibacterium lactatiformans</i> and <i>Akkermansia</i> and decreased <i>Blautia wexlerae</i>, <i>Dorea formicigenerans</i>, and <i>Erysipelotrichaceae CCM</i>. Unique to progressive MS, we found elevated <i>Enterobacteriaceae</i> and <i>Clostridium g24 FCEY</i> and decreased <i>Blautia</i> and <i>Agathobaculum</i>. Several <i>Clostridium</i> species were associated with higher EDSS and fatigue scores. Contrary to the view that elevated <i>Akkermansia</i> in MS has a detrimental role, we found that <i>Akkermansia</i> was linked to lower disability, suggesting a beneficial role. Consistent with this, we found that <i>Akkermansia</i> isolated from MS patients ameliorated EAE, which was linked to a reduction in RORγt+ and IL‐17 producing γδ T cells. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Interpretation</h3><p>While some microbiota alterations are shared in relapsing and progressive MS, we identified unique bacteria associated with progressive MS and clinical measures of disease. Furthermore, elevated <i>Akkermansia</i> in MS may be a compensatory beneficial response in the MS microbiome. </p><p>This article is protected by copyright. All rights reserved.</p></section>
neurosciences,clinical neurology